The decreased sensitivity to MEK inhibition in cancer cells containing oncogenic KRAS mutations is likely due to another RAS-effector pathways (e.g. PI3K pathway) that can maintain cell proliferation and survival (Figure 4B). Here, KRAS is linked to cancer.